Duravyu (vorolanib intravitreal insert)

Name: Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: American hospital formulary service (AHFS), or other drug classification
Published: 2026-09-17T18:16:06-04:00

Wet age-related macular degeneration

Also known as EYP-1901

Manufacturer: EyePoint
Regulatory submission: NDA planned for the first half of 2027
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

American hospital formulary service (AHFS), or other drug classification

2 evidence topics · 1 source

Mechanistic classification: type II pan-VEGFR tyrosine kinase inhibitor

“Our modeling results predict that vorolanib strongly binds intracellularly near the ATP binding regions of VEGFR1, VEGFR2, and VEGFR3 when the VEGFRs are in the DFG-out (inactive) configuration, making vorolanib a type II pan-VEGFR inhibitor.” (opens the source at this quote in a new tab)

Prior approval of oral vorolanib outside ophthalmology

“vorolanib tablets in combination with everolimus were approved in 2023 by China’s National Medical Products Administration for the treatment of advanced renal cell carcinoma” (opens the source at this quote in a new tab)

AHFS classification

No evidence found.